Yoshiaki Kitamura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yoshiaki Kitamura has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Noriaki Takeda
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima, Japan
15 shared publications Tatsuya Fujii
Department of Otolaryngology, JA Kochi Hospital, Kochi, Japan
9 shared publicationsHiroyuki Fukui
Department of Otolaryngology Institute of Biomedical Sciences, Tokushima University Graduate School Tokushima Japan
8 shared publicationsNoriaki Takeda
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan
8 shared publications- Seiichiro Kamimura
Department of Otolaryngology-Head and Neck Surgery, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan
8 shared publications - Hiroyuki Mizuguchi
Laboratory of Pharmacology, Faculty of Pharmacy, Osaka Ohtani University, Osaka 584-8540, Japan
7 shared publications
Latest Publications
- Open Access
- 12 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
A CD4+ T cell-fibroblast crosstalk exacerbates autoimmunity in a mouse model of primary Sjögren disease
CD4+ T cells are key drivers of immune-mediated tissue damage and participate in complex cellular interactions that perpetuate chronic inflammation. However, the specific subsets of pathogenic CD4+ T cells and their non-immune cell partners are less well characterized. Here, we use a mouse model of primary Sjögren disease (pSjD) and identify CD153+CD4+ T cells as critical drivers of inflammation during the early stages of autoimmune pathology. We describe a CD153+CD4+ T cell-CD30+ tissue-resident fibroblast interaction that promotes fibroblast proliferation and chemokine secretion, further driving immune cell infiltration and thereby amplifying the autoimmune response. Importantly, deletion of CD153 in CD4+ T cells or neutralization of fibroblast-derived chemokines reduces lymphocytic infiltration and significantly halts autoimmune-like pathology. The CD153-CD30 axis positively correlates with disease severity in human patients. Thus, our results describe a pathogenic, therapeutically targetable CD153+CD4+ T cell-CD30+ fibroblast axis that perpetuates chronic inflammation in pSjD.
- 12 May 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Open AccessA CD4+ T cell-fibroblast crosstalk exacerbates autoimmunity in a mouse model of primary Sjögren disease
CD4+ T cells are key drivers of immune-mediated tissue damage and participate in complex cellular interactions that perpetuate chronic inflammation. However, the specific subsets of pathogenic CD4+ T cells and their non-immune cell partners are less well characterized. Here, we use a mouse model of primary Sjögren disease (pSjD) and identify CD153+CD4+ T cells as critical drivers of inflammation during the early stages of autoimmune pathology. We describe a CD153+CD4+ T cell-CD30+ tissue-resident fibroblast interaction that promotes fibroblast proliferation and chemokine secretion, further driving immune cell infiltration and thereby amplifying the autoimmune response. Importantly, deletion of CD153 in CD4+ T cells or neutralization of fibroblast-derived chemokines reduces lymphocytic infiltration and significantly halts autoimmune-like pathology. The CD153-CD30 axis positively correlates with disease severity in human patients. Thus, our results describe a pathogenic, therapeutically targetable CD153+CD4+ T cell-CD30+ fibroblast axis that perpetuates chronic inflammation in pSjD.
- 3 March 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 309-323
Vestibular assessment in definite cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): A case of siblings study
- 3 March 2026
- Published by Elsevier in Auris Nasus Larynx
- Vol. 53 (3) , 309-323
Vestibular assessment in definite cerebellar Ataxia, Neuropathy, Vestibular Areflexia Syndrome (CANVAS): A case of siblings study
- Open Access
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
High Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- 18 November 2025
- Published by Wiley in Laryngoscope Investigative Otolaryngology
- Vol. 10 (6)
Open AccessHigh Remission Rate in Eosinophilic Chronic Rhinosinusitis Following More Than Two Years of Dupilumab Therapy
Objective: This study aimed to evaluate the clinical remission rate and changes in medication use in patients with eosinophilic chronic rhinosinusitis (ECRS) treated with dupilumab for > 2 years. Methods: This retrospective study included 19 patients with ECRS who received dupilumab therapy for > 2 years. The nasal polyp, Lund–Mackay on sinus CT, and SNOT‐22 scores were assessed at baseline, 3 months, 1 year, and at the final evaluation. Remission was defined as sustained fulfillment of specific clinical and endoscopic criteria for at least 12 months. The use of concomitant medications was also assessed. Results: Polyp score significantly improved from 6.1 ± 0.6 at baseline to 0.68 ± 1.2 at final evaluation. SNOT‐22 scores decreased from 42.8 ± 20.0 to 14.1 ± 10.2. Clinical remission was achieved in 15 patients (79%). The remaining four patients did not meet the remission criteria because of persistent olfactory dysfunction or nasal obstruction. Significant reductions in the use of oral corticosteroids, drop‐type intranasal corticosteroids, nasal spray corticosteroids, leukotriene receptor antagonists, and inhaled corticosteroids were also observed. Conclusion: Dupilumab therapy for > 2 years resulted in a high clinical remission rate and reduced the need for concomitant medications in patients with ECRS. Persistent olfactory dysfunction is the main reason for non‐remission, indicating the need for further therapeutic strategies in such refractory cases. Level of Evidence: 3.
- Open Access
- 21 October 2025
- Published by Elsevier in Oral Oncology Reports
- Vol. 16
Durable partial response of pulmonary metastases from primary sublingual gland squamous cell carcinoma after pembrolizumab failure: Salvage therapy with paclitaxel plus cetuximab
- 21 October 2025
- Published by Elsevier in Oral Oncology Reports
- Vol. 16
Open AccessDurable partial response of pulmonary metastases from primary sublingual gland squamous cell carcinoma after pembrolizumab failure: Salvage therapy with paclitaxel plus cetuximab
- Open Access
- 5 January 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101555
Effect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
- 5 January 2025
- Published by Elsevier in Brazilian Journal of Otorhinolaryngology
- Vol. 91 (2) , 101555
Open AccessEffect of dupilumab on otitis media associated with eosinophilic chronic rhinosinusitis
- Open Access
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (1.2) , 14-20
Recent advances in the management of allergic rhinitis
Allergic rhinitis (AR) is a type I allergic disease characterized by sneezing, watery rhinorrhea, and nasal obstruction. An epidemiological survey found that approximately 50% of Japanese individuals have AR.Histamine is a major chemical mediator that induces AR symptoms through its binding to histamine H1 receptor(H1R). We demonstrated that antihistamines have a blocking effect on histamine signaling of H1R, and the suppressive effect on histamine-induced up-regulation of transcriptional activation, and the suppressive effect on basal transcription of H1R in the absence of histamine which may be part of the inverse agonist action of antihistamine. Sublingual immunotherapy (SLIT) with a standardized Japanese cedar (JC) pollen significantly improved nasal symptoms and AR-related sleep disturbance in patients with JC pollinosis. Dual SLIT with JC pollen and house dust mites (HDM) suppressed both JC pollen-induced seasonal and HDM-induced perennial nasal symptoms in bisensitized patients with AR. Dual SLIT was more effective in suppressing nasal obstruction at the peak JC pollen period than mono SLIT with JC pollen. Posterior nasal neurectomy (PNN) improved nasal symptoms and medication scores in patients with severe perennial AR. Herein, we describe recent advances in the management of AR. J. Med. Invest. 72 : 14-20, February, 2025
- 1 January 2025
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 72 (1.2) , 14-20
Open AccessRecent advances in the management of allergic rhinitis
Allergic rhinitis (AR) is a type I allergic disease characterized by sneezing, watery rhinorrhea, and nasal obstruction. An epidemiological survey found that approximately 50% of Japanese individuals have AR.Histamine is a major chemical mediator that induces AR symptoms through its binding to histamine H1 receptor(H1R). We demonstrated that antihistamines have a blocking effect on histamine signaling of H1R, and the suppressive effect on histamine-induced up-regulation of transcriptional activation, and the suppressive effect on basal transcription of H1R in the absence of histamine which may be part of the inverse agonist action of antihistamine. Sublingual immunotherapy (SLIT) with a standardized Japanese cedar (JC) pollen significantly improved nasal symptoms and AR-related sleep disturbance in patients with JC pollinosis. Dual SLIT with JC pollen and house dust mites (HDM) suppressed both JC pollen-induced seasonal and HDM-induced perennial nasal symptoms in bisensitized patients with AR. Dual SLIT was more effective in suppressing nasal obstruction at the peak JC pollen period than mono SLIT with JC pollen. Posterior nasal neurectomy (PNN) improved nasal symptoms and medication scores in patients with severe perennial AR. Herein, we describe recent advances in the management of AR. J. Med. Invest. 72 : 14-20, February, 2025
- 5 June 2024
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (4) , 733-737
Effects of sodium bicarbonate solution on hypergravity-induced Fos expression in neurons of the amygdala in rats: Implication of sodium bicarbonate therapy for vertigo
- 5 June 2024
- Published by Elsevier in Auris Nasus Larynx
- Vol. 51 (4) , 733-737
Effects of sodium bicarbonate solution on hypergravity-induced Fos expression in neurons of the amygdala in rats: Implication of sodium bicarbonate therapy for vertigo
- Open Access
- 1 January 2024
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 71 (3.4) , 273-278
Location of ethmoidal arteries in relation to ethmoid cells and the anterior skull base
Background:Ethmoidal arteries are at risk of accidental injury during endoscopic sinus surgery (ESS). Aims/Objectives:We aimed to examine the location of ethmoidal arteries in relation to ethmoid cells and the anterior skull base (ASB) in Japanese patients. Material and Methods:CT images of 100 sides of 50 patients were retrospectively reviewed. The location of anterior ethmoidal arteries (AEAs), middle ethmoidal arteries (MEAs) and posterior ethmoidal arteries (PEAs) in relation to ethmoidal cells and their distance from the ASB were evaluated. Results:AEAs and PEAs were present in all sides. 60% of AEAs and 9% of PEAs ran below the level of ASB. MEAs were present in 21 sides and ran below the ASB in 23.8% (5/21) of these sides. The incidence of AEAs running below the level of ASB was significantly higher in the sides with supraorbital ethmoid cells (SOECs) than in those without SOECs. Conclusion and significance:This study revealed the position and the distance from ASB of AEAs, PEAs, and MEAs in relation to ethmoid cells in Japanese patients. In cases with SOECs, surgeons should be careful not to injure the AEAs running below the level of ASB. J. Med. Invest. 71 : 273-278, August, 2024
- 1 January 2024
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 71 (3.4) , 273-278
Open AccessLocation of ethmoidal arteries in relation to ethmoid cells and the anterior skull base
Background:Ethmoidal arteries are at risk of accidental injury during endoscopic sinus surgery (ESS). Aims/Objectives:We aimed to examine the location of ethmoidal arteries in relation to ethmoid cells and the anterior skull base (ASB) in Japanese patients. Material and Methods:CT images of 100 sides of 50 patients were retrospectively reviewed. The location of anterior ethmoidal arteries (AEAs), middle ethmoidal arteries (MEAs) and posterior ethmoidal arteries (PEAs) in relation to ethmoidal cells and their distance from the ASB were evaluated. Results:AEAs and PEAs were present in all sides. 60% of AEAs and 9% of PEAs ran below the level of ASB. MEAs were present in 21 sides and ran below the ASB in 23.8% (5/21) of these sides. The incidence of AEAs running below the level of ASB was significantly higher in the sides with supraorbital ethmoid cells (SOECs) than in those without SOECs. Conclusion and significance:This study revealed the position and the distance from ASB of AEAs, PEAs, and MEAs in relation to ethmoid cells in Japanese patients. In cases with SOECs, surgeons should be careful not to injure the AEAs running below the level of ASB. J. Med. Invest. 71 : 273-278, August, 2024
- Open Access
- 1 January 2024
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 71 (3.4) , 310-313
Orbital apex syndrome secondary to acute invasive fungal rhinosinusitis diagnosed by transnasal endoscopic biopsy of the optic canal:A case report
Orbital apex syndrome (OAS) is a complex condition characterized by visual loss, diplopia, and eye pain that occurs secondary to several pathological processes involving the orbital apex. We report a case of acute invasive fungal rhinosinusitis (AIFRS) associated with OAS. A 76-year-old man with left-sided visual loss, diplopia, palpebral ptosis, and headache was diagnosed with OAS secondary to Tolosa-Hunt syndrome and received systemic corticosteroid therapy from his neurologist. Owing to persistent symptoms, we opened the optic canal using a transnasal endoscopic approach for a surgical biopsy of the orbital apex lesions. Histopathological evaluation revealed numerous Aspergillus organisms in the biopsied granuloma. After surgical debridement, he received a 12-month course of voriconazole, and no recurrence of AIFRS occurred during 8-year follow-up. Patients with OAS may occasionally be prescribed corticosteroids because the clinical manifestations of AIFRS-induced OAS are similar to those observed in OAS secondary to Tolosa-Hunt syndrome, especially no nasal symptoms which is known to respond to corticosteroid therapy. Because both AIFRS-induced OAS and OAS secondary to Tolosa-Hunt syndrome induce ophthalmoplegia, proptosis, eye pain, it is sometimes difficult to differentiate these two diseases in early stage. However, corticosteroid therapy causes exacerbation of fungal infection in patients with AIFRS-induced OAS resulting in delayed accurate diagnosis and poor prognosis. AIFRS is associated with a high mortality rate ; therefore, transnasal endoscopic biopsy of orbital apex lesions before corticosteroid administration is recommended in patients with OAS. J. Med. Invest. 71 : 310-313, August, 2024
- 1 January 2024
- Published by University of Tokushima Faculty of Medicine in The Journal of Medical Investigation
- Vol. 71 (3.4) , 310-313
Open AccessOrbital apex syndrome secondary to acute invasive fungal rhinosinusitis diagnosed by transnasal endoscopic biopsy of the optic canal:A case report
Orbital apex syndrome (OAS) is a complex condition characterized by visual loss, diplopia, and eye pain that occurs secondary to several pathological processes involving the orbital apex. We report a case of acute invasive fungal rhinosinusitis (AIFRS) associated with OAS. A 76-year-old man with left-sided visual loss, diplopia, palpebral ptosis, and headache was diagnosed with OAS secondary to Tolosa-Hunt syndrome and received systemic corticosteroid therapy from his neurologist. Owing to persistent symptoms, we opened the optic canal using a transnasal endoscopic approach for a surgical biopsy of the orbital apex lesions. Histopathological evaluation revealed numerous Aspergillus organisms in the biopsied granuloma. After surgical debridement, he received a 12-month course of voriconazole, and no recurrence of AIFRS occurred during 8-year follow-up. Patients with OAS may occasionally be prescribed corticosteroids because the clinical manifestations of AIFRS-induced OAS are similar to those observed in OAS secondary to Tolosa-Hunt syndrome, especially no nasal symptoms which is known to respond to corticosteroid therapy. Because both AIFRS-induced OAS and OAS secondary to Tolosa-Hunt syndrome induce ophthalmoplegia, proptosis, eye pain, it is sometimes difficult to differentiate these two diseases in early stage. However, corticosteroid therapy causes exacerbation of fungal infection in patients with AIFRS-induced OAS resulting in delayed accurate diagnosis and poor prognosis. AIFRS is associated with a high mortality rate ; therefore, transnasal endoscopic biopsy of orbital apex lesions before corticosteroid administration is recommended in patients with OAS. J. Med. Invest. 71 : 310-313, August, 2024